Day 1 :
Keynote Forum
Francesca J Torriani
University of California, USA
Keynote: Refocusing on standard precautions and other non-pathogen-specific initiatives to prevent nosocomial transmission of bacterial pathogens in the acute healthcare settings
Biography:
Abstract:
Keynote Forum
Ionel Victor Pătraşcu
Activeimmunity srl, Romania
Keynote: Biological products pi-2a II-oral and topical treatment of pediatric psoriasis
Time : 10:40 AM- 11:20 AM
Biography:
Abstract:
Keynote Forum
Ionel Victor Pătraşcu
Activeimmunity srl, Romania
Keynote: Biological products pi-2a II-oral and topical treatment of pediatric psoriasis
Time : 10:40 AM- 11:20 AM
Biography:
Abstract:
Keynote Forum
Sharad Kumar Yadav
Veterinary University, India
Keynote: Recent advances in phage display technology
Biography:
Abstract:
Emergence of prokaryotic and eukaryotic expression system for the use of antibody production in the beginning years of 1980s was a surprise entry for the new era of ‘IMMUNOTECHNOLOGY’ [a branch of biotechnology that employs sets to bio-technique for the production of immunobiologicals]. Entry of phage display system during the years of 1990s for the antibody fragment expression has been created a bigger achievement and turned into a milestone, which concludes the method of phage display technology for the production of small fragments of antibodies that must possess the quality and the characteristic of binding to the antigens specifically which are popularly and most commonly known as Nanobodies. Phage display technology is a simpler, less time consuming and more efficient approach than the conventional methodology of the antibody production, which contains a number of component for the production of small fragment specific antibodies that includes the target or the antigen in anticipation to the ligand or binder or the antibody which are meant to be produced, next to this it concludes a Phage Display Library, A Phage system, Appropriate Selection or screening process, Appropriate Expression and purification system. The most common bacteriophages used are M13, and FD filamentous phage, though T4, T7 and λ Phage have also been used in some cases.
- Immunization | Nosocomial Infections & Control | Pulmonary Infection Therapy | Infection Prevention and Control | Hospital Infections and Epidemiology | Personal Hygiene Practices | Blood Borne and Exposure Control
Location: Valencia, Spain
Chair
Julian Hunt
Swansea University, UK
Co-Chair
Francesca J Torriani
University of California, USA
Session Introduction
Sumaiah Farook
Apollo Hospital Muscat
Oman
Title: Hand hygiene perception survey among healthcare workers in a tertiary hospital in Oman
Biography:
Abstract:
Biography:
Abstract:
Usman Rasool Lodhi
Provincial Tuberculosis Control Program – Punjab
Pakistan
Title: Treatment outcomes and their association with type of resistance among drug resistant tuberculosis patients during 2014-2015 in Punjab, Pakistan: A retrospective cohort analysis
Biography:
Abstract:
Manuel R Velasco
VRP Medical Center
Philippines
Title: A case report on a rare case of tuberculosis of the pancreas presenting as pancreatic mass
Biography:
Abstract:
Biography:
Abstract:
Nidia Leon-Sicairos
Hospital Pediatrico de Sinaloa
Mexico
Title: Effect of lactoferrin-derived synthetic peptides on salmonella enterica ATCC 14028 planktonic cells and biofilms
Biography:
Abstract:
Tudor Georgescu
Active Immunity srl
Romania
Title: Chicken immunological active protein (CIAP). The immunoVIP (IVIP)group of products from an integrated perspective: Applicative research, transfer of technology, productions, clinical use
Time : 16:20 PM-17:00 PM
Biography:
Abstract:
- Infection Control in Critical Care | Infection Control Risk Assessment | Plant Pathology and Diseases Control | Emerging and Re-Emerging Infections | Infection Control in Clinical Practice | Antimicrobial Chemotherapy | Infections During Pregnancy
Location: Valencia
Chair
Julian Hunt
Swansea University, UK
Co-Chair
Francesca J Torriani
University of California, USA
Session Introduction
Liliana Viasu
Teaching Hospital of Nephrology dr.Carol Davila
Romania
Title: Chicken immunological active proteins (CIAP). The specific reaction against multiple resistance bacterial strains in urinary tract infections
Biography:
Liliana Viasu MD, head of Laboratory at Teaching Hospital of Nephrology dr.Carol Davila ,Bucharest, Romania and scientific manager of Autoimmunity SRL. Born in 24th June 1970,graduated in University of Medicine and Pharmacy Carol Davila in Bucharest in 1998.Specialization in Laboratory Medicine, especially Immunology.20 years of research in autoimmunity, hematology, bone metabolism, immunological disorders also specialization in Translational Medicine. In the last 2 years participate at the program for Antibiotic resistance of microorganisms, preclinical and clinical human studies and the second generation of immunogen I-spga that was managed to prepare IMUNOVIP able to react specifically with bacteria by oral treatment of antibiotic-resistant urinary tract infections in women. All the latest studies were made in collaboration with Pătrașcu Ionel Victor, MVD, PhD president of Activeimmunity SRL.
Abstract:
Ioana Manea
Activeimmunity srl
Romania
Title: Chicken immunologically active proteins for the development of anti-idiotypic vaccines
Biography:
Ioana Manea is a medical doctor currently in her fourth year of residency, specializing in Laboratory Medicine (Clinical Laboratory). She obtained her medical degree from ”Carol Davila” University of Medicine and Pharmacy, Bucharest in 2014. She is currently collaborating with Activeimmunity in the Microbiology and Immunology research department.
Abstract:
Violeta Ionescu
Active Immunity srl
Romania